Attana and ExpreS[2]ion Biotech have signed a Development & Supply Agreement
Attana AB (“Attana”) hereby announces that it has signed a heads of terms agreement regarding the development and supply of novel proteins from ExpreS[2]ion Biotechnologies ApS (“ExpreS[2]ion"). The first target protein will be the ExpreS[2]ion-produced SARS-CoV-2 spike and receptor-binding-domain (RBD) antigen used in ExpreS[2]ion’s COVID-19 vaccine program. Attana will now be able to offer customers utilising its AVA diagnostic platform, this and other novel ExpreS[2]ion proteins. The parties are not disclosing the commercial terms of the agreement.In early June, ExpreS[2]ion announced (